immunosuppressant (CERES)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameimmunosuppressant (CERES)
Drug Alias Namefas ligand (CERES)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase inhibitorsApoptosis-mediating surface antigen FAS stimulants
TargetsPoly (ADP-Ribose) polymeraseApoptosis-mediating surface antigen FAS
Therapy Area/IndicationsRejection of organ transplantationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlobeimmune Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlobeimmune Inc
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A